Bookmark and Share

Compound Summary for: CID 11626560

crizotinib

Also known as: 877399-52-5; PF-2341066; Xalkori; PF 2341066; PF-02341066
Molecular Formula: C21H22Cl2FN5O   Molecular Weight: 450.336683   InChIKey: KTEIFNKAUNYNJU-GFCCVEGCSA-N
Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.    From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Pharmacology
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _